Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concomitant Irradiation to Checkpoint Inhibitor Therapy of Hepatocellular Carcinoma Patients: A Systematic Retrospective, Single-Center Analysis.
Munker S, Roessler D, Öcal O, Ben-Khaled N, Bernhart K, Ye L, Piseddu I, Vielhauer J, Reiter FP, Rodriguez I, Ricke J, Teufel A, De Toni E, Seidensticker M, Niyazi M, Corradini S. Munker S, et al. Among authors: ben khaled n. Oncol Res Treat. 2023;46(11):466-475. doi: 10.1159/000533983. Epub 2023 Oct 12. Oncol Res Treat. 2023. PMID: 37827135 Free PMC article.
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D, Öcal O, Philipp AB, Markwardt D, Munker S, Mayerle J, Jochheim LS, Hammer K, Lange CM, Geier A, Seidensticker M, Reiter FP, De Toni EN, Ben Khaled N. Roessler D, et al. J Cancer Res Clin Oncol. 2023 Jul;149(7):3065-3073. doi: 10.1007/s00432-022-04206-8. Epub 2022 Jul 21. J Cancer Res Clin Oncol. 2023. PMID: 35864269 Free PMC article.
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Öcal O, Schütte K, Kupčinskas J, Morkunas E, Jurkeviciute G, de Toni EN, Ben Khaled N, Berg T, Malfertheiner P, Klümpen HJ, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Palmer D, Seidensticker R, Wildgruber M, Sangro B, Pech M, Ricke J, Seidensticker M. Öcal O, et al. J Cancer Res Clin Oncol. 2022 Feb;148(2):475-485. doi: 10.1007/s00432-021-03627-1. Epub 2021 Apr 14. J Cancer Res Clin Oncol. 2022. PMID: 33855585 Free PMC article. Clinical Trial.
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
Ben Khaled N, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rössler D, Teupser D, Ehmer U, Bitzer M, Waldschmidt D, Fuchs M, Reuken PA, Lange CM, Wege H, Kandulski A, Dechêne A, Venerito M, Berres ML, Luedde T, Kubisch I, Reiter FP, De Toni EN. Ben Khaled N, et al. Future Oncol. 2022 Apr;18(12):1423-1435. doi: 10.2217/fon-2021-1261. Epub 2022 Jan 27. Future Oncol. 2022. PMID: 35081747
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study.
Ben Khaled N, Mörtl B, Beier D, Reiter FP, Pawlowska-Phelan D, Teufel A, Rössler D, Schwade DF, Philipp A, Kubisch I, Ehmer U, Geier A, Lange CM, Mayerle J, Berger-Thürmel K, De Toni EN, Munker S. Ben Khaled N, et al. Eur J Cancer. 2023 Oct;192:113248. doi: 10.1016/j.ejca.2023.113248. Epub 2023 Jul 21. Eur J Cancer. 2023. PMID: 37672814
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.
Seidensticker M, Öcal O, Schütte K, Malfertheiner P, Berg T, Loewe C, Klümpen HJ, van Delden O, Ümütlü MR, Ben Khaled N, de Toni EN, Seidensticker R, Aghdassi A, Tran A, Bronowicki JP, Peynircioglu B, Sangro B, Pech M, Ricke J. Seidensticker M, et al. JHEP Rep. 2023 Feb 15;5(5):100699. doi: 10.1016/j.jhepr.2023.100699. eCollection 2023 May. JHEP Rep. 2023. PMID: 36968218 Free PMC article.
34 results